Literature DB >> 21576818

Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.

Lee Adam Wheeler1, Radiana Trifonova, Vladimir Vrbanac, Emre Basar, Shannon McKernan, Zhan Xu, Edward Seung, Maud Deruaz, Tim Dudek, Jon Ivar Einarsson, Linda Yang, Todd M Allen, Andrew D Luster, Andrew M Tager, Derek M Dykxhoorn, Judy Lieberman.   

Abstract

The continued spread of the HIV epidemic underscores the need to interrupt transmission. One attractive strategy is a topical vaginal microbicide. Sexual transmission of herpes simplex virus type 2 (HSV-2) in mice can be inhibited by intravaginal siRNA application. To overcome the challenges of knocking down gene expression in immune cells susceptible to HIV infection, we used chimeric RNAs composed of an aptamer fused to an siRNA for targeted gene knockdown in cells bearing an aptamer-binding receptor. Here, we showed that CD4 aptamer-siRNA chimeras (CD4-AsiCs) specifically suppress gene expression in CD4⁺ T cells and macrophages in vitro, in polarized cervicovaginal tissue explants, and in the female genital tract of humanized mice. CD4-AsiCs do not activate lymphocytes or stimulate innate immunity. CD4-AsiCs that knock down HIV genes and/or CCR5 inhibited HIV infection in vitro and in tissue explants. When applied intravaginally to humanized mice, CD4-AsiCs protected against HIV vaginal transmission. Thus, CD4-AsiCs could be used as the active ingredient of a microbicide to prevent HIV sexual transmission.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576818      PMCID: PMC3104760          DOI: 10.1172/JCI45876

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

Review 1.  Targeting early infection to prevent HIV-1 mucosal transmission.

Authors:  Ashley T Haase
Journal:  Nature       Date:  2010-03-11       Impact factor: 49.962

2.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

3.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Authors:  Nan Sook Lee; Taikoh Dohjima; Gerhard Bauer; Haitang Li; Ming-Jie Li; Ali Ehsani; Paul Salvaterra; John Rossi
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

4.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

5.  Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.

Authors:  A B van't Wout; N A Kootstra; G A Mulder-Kampinga; N Albrecht-van Lent; H J Scherpbier; J Veenstra; K Boer; R A Coutinho; F Miedema; H Schuitemaker
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

6.  T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice.

Authors:  Priti Kumar; Hong-Seok Ban; Sang-Soo Kim; Haoquan Wu; Todd Pearson; Dale L Greiner; Amale Laouar; Jiahong Yao; Viraga Haridas; Katsuyoshi Habiro; Yong-Guang Yang; Ji-Hoon Jeong; Kuen-Yong Lee; Yong-Hee Kim; Sung Wan Kim; Matthias Peipp; Georg H Fey; N Manjunath; Leonard D Shultz; Sang-Kyung Lee; Premlata Shankar
Journal:  Cell       Date:  2008-08-07       Impact factor: 41.582

7.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

8.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

9.  Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference.

Authors:  Glen A Coburn; Bryan R Cullen
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages.

Authors:  Erwei Song; Sang-Kyung Lee; Derek M Dykxhoorn; Carl Novina; Dong Zhang; Keith Crawford; Jan Cerny; Phillip A Sharp; Judy Lieberman; N Manjunath; Premlata Shankar
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more
  108 in total

Review 1.  Drug resistance in HIV-1.

Authors:  Daniel R Kuritzkes
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

2.  Cell-penetrating RNAs: new keys to the castle.

Authors:  Donald H Burke
Journal:  Mol Ther       Date:  2012-02       Impact factor: 11.454

Review 3.  Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice.

Authors:  Paul W Denton; J Victor Garcia
Journal:  Trends Microbiol       Date:  2012-04-12       Impact factor: 17.079

Review 4.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

Review 5.  Current progress in the development of RNAi-based therapeutics for HIV-1.

Authors:  J Zhou; J J Rossi
Journal:  Gene Ther       Date:  2011-09-29       Impact factor: 5.250

Review 6.  Nucleic acid aptamers: clinical applications and promising new horizons.

Authors:  X Ni; M Castanares; A Mukherjee; S E Lupold
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 7.  Recent developments in protein and cell-targeted aptamer selection and applications.

Authors:  Jun Liu; Mingxu You; Ying Pu; Huixia Liu; Mao Ye; Weihong Tan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

8.  ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.

Authors:  Rikke Olesen; Michael D Swanson; Martina Kovarova; Tomonori Nochi; Morgan Chateau; Jenna B Honeycutt; Julie M Long; Paul W Denton; Michael G Hudgens; Amy Richardson; Martin Tolstrup; Lars Østergaard; Angela Wahl; J Victor Garcia
Journal:  J Clin Invest       Date:  2016-02-08       Impact factor: 14.808

9.  Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.

Authors:  Brett Schrand; Alexey Berezhnoy; Randall Brenneman; Anthony Williams; Agata Levay; Ling-Yuan Kong; Ganesh Rao; Shouhao Zhou; Amy B Heimberger; Eli Gilboa
Journal:  Cancer Immunol Res       Date:  2014-06-17       Impact factor: 11.151

Review 10.  Knocking down disease: a progress report on siRNA therapeutics.

Authors:  Anders Wittrup; Judy Lieberman
Journal:  Nat Rev Genet       Date:  2015-09       Impact factor: 53.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.